Bioventus Inc. Class A Common Stock (BVS)

Price$7.93

Value ScoreB

Growth ScoreC

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)14.39%

Price vs S&P 500 (4W)-20.80%

VGM Score58.98

Market Capitalization$710.88M

P/E Ratio (Annual)31.27x

All Metrics

P/CF (Annual)9.52x

Book Value / Share (Quarterly)$2.26

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)3.52%

Cash Flow / Share (Quarterly)$1.21

Price vs S&P 500 (YTD)3.45%

Gross Margin (TTM)68.69%

Net Profit Margin (TTM)4.94%

EPS (TTM)$0.41

10-Day Avg Trading Volume0.73M

EPS Excl Extra (TTM)$0.41

Revenue Growth (5Y)12.08%

EPS (Annual)$0.33

ROI (Annual)4.66%

Gross Margin (Annual)68.33%

Net Profit Margin (5Y Avg)-11.86%

Cash / Share (Quarterly)$0.43

P/E Basic Excl Extra (TTM)24.96x

Revenue Growth QoQ (YoY)6.63%

EPS Growth (5Y)2.26%

P/E Normalized (Annual)31.27x

ROA (Last FY)3.33%

Revenue Growth TTM (YoY)1.52%

EBITD / Share (TTM)$0.90

ROE (5Y Avg)-29.59%

Operating Margin (TTM)9.92%

Cash Flow / Share (Annual)$0.87

P/B Ratio3.76x

P/B Ratio (Quarterly)3.94x

Net Income / Employee (Annual)$24,400

EV / Revenue (TTM)1.66x

Net Interest Coverage (TTM)2.02x

ROA (TTM)4.15%

EV / EBITDA (TTM)15.32x

EPS Incl Extra (Annual)$0.33

Current Ratio (Annual)1.70x

Quick Ratio (Quarterly)1.06x

3-Month Avg Trading Volume0.44M

52-Week Price Return29.73%

EV / Free Cash Flow (Annual)13.26x

P/E Incl Extra (TTM)24.96x

Revenue / Employee (TTM)$619,700

Tangible BV / Share (Quarterly)$-4.10

P/S Ratio (Annual)1.25x

Asset Turnover (Annual)0.83x

52-Week High$11.25

Operating Margin (5Y Avg)-11.17%

EPS Excl Extra (Annual)$0.33

CapEx CAGR (5Y)-8.93%

26-Week Price Return30.32%

Quick Ratio (Annual)1.12x

13-Week Price Return-3.95%

Total Debt / Equity (Annual)1.65x

Current Ratio (Quarterly)1.69x

Enterprise Value$956.52M

Revenue / Share Growth (5Y)7.37%

Asset Turnover (TTM)0.84x

Revenue / Employee (Annual)$610,800

Inventory Turnover (Annual)2.06x

Pretax Margin (Annual)4.53%

Cash / Share (Annual)$0.62

3-Month Return Std Dev51.62%

Gross Margin (5Y Avg)67.00%

Net Income / Employee (TTM)$30,600

EBITDA CAGR (5Y)12.60%

EBITDA Interim CAGR (5Y)-16.81%

ROE (Last FY)12.35%

Net Interest Coverage (Annual)2.53x

EPS Basic Excl Extra (Annual)$0.33

P/FCF (TTM)7.06x

Receivables Turnover (TTM)4.83x

EV / Free Cash Flow (TTM)9.51x

Total Debt / Equity (Quarterly)1.49x

EPS Incl Extra (TTM)$0.41

Receivables Turnover (Annual)4.44x

ROI (TTM)5.79%

P/S Ratio (TTM)1.23x

Pretax Margin (5Y Avg)-15.60%

Revenue / Share (Annual)$8.24

Tangible BV / Share (Annual)$-9.45

Forward P/E10.24x

Free OCF CAGR (5Y)1.27%

Price vs S&P 500 (52W)1.52%

P/E Ratio (TTM)24.96x

Year-to-Date Return14.38%

5-Day Price Return-8.30%

EPS Normalized (Annual)$0.33

ROA (5Y Avg)-6.18%

Net Profit Margin (Annual)4.00%

Month-to-Date Return-13.78%

Cash Flow / Share (TTM)$-1.35

EBITD / Share (Annual)$0.86

Operating Margin (Annual)9.44%

LT Debt / Equity (Annual)1.52x

P/CF (TTM)6.91x

ROI (5Y Avg)-9.77%

P/E Excl Extra (TTM)24.96x

LT Debt / Equity (Quarterly)1.34x

EPS Basic Excl Extra (TTM)$0.41

P/B Ratio (Annual)3.34x

Inventory Turnover (TTM)2.04x

Pretax Margin (TTM)5.84%

Book Value / Share (Annual)$2.22

Price vs S&P 500 (13W)-13.70%

Net Margin Growth (5Y)-4.78%

Beta0.70x

P/FCF (Annual)9.86x

Revenue / Share (TTM)$8.23

ROE (TTM)16.27%

52-Week Low$5.81

vGradeB

gGradeC

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 260.15est. 0.10

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.00

4.13

4.11

Industry Peers — Surgical & Medical Instruments(138)

Symbol	Value Score	Growth Score	Momentum Score	Price
BVSBioventus Inc. Class A Common Stock	B	C	C	$7.93
SYKStryker Corporation	C	C	D	$299.46
MMM3M Company	C	F	C	$150.93
BSXBoston Scientific Corp.	C	B	F	$47.98
MDLNMedline Inc. Class A common stock	C	D	D	$35.75
BDXBecton, Dickinson and Co.	B	C	C	$145.33
DXCMDexCom, Inc.	C	B	C	$74.87
RMDResMed Inc.	B	B	D	$186.44
WSTWest Pharmaceutical Services, Inc.	D	C	B	$316.30
SOLVSolventum Corporation	C	D	C	$75.84
PENPenumbra, Inc.	F	C	C	$318.95

About

Bioventus Inc. is a medical technology company that develops clinically differentiated treatments enhancing natural healing processes across the orthopedic continuum. Its product portfolio serves multiple orthopedic specialties—including sports medicine, joint reconstruction, trauma, and spine surgery—organized into three verticals: Pain Treatments, Surgical Solutions, and Restorative Therapies. The company generates key revenue in the United States with growing international market presence.